All In Biotech

Free tool

FAERS Monitor: Zelboraf

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 202429 or its brand name (Zelboraf, Vemurafenib). Reports on generic versions are filed under their own applications.

Reports

11,990

Serious

8,963

75% of reports

Hospitalization

3,403

Death reported

2,076

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • rash1,554
  • death1,065
  • arthralgia1,043
  • fatigue1,039
  • off label use875
  • diarrhoea828
  • nausea812
  • disease progression768
  • pyrexia744
  • alopecia563
  • decreased appetite534
  • vomiting475
  • photosensitivity reaction415
  • pruritus390
  • sunburn373

Reports by year received

View as table
YearReports
20091
2011167
20121,408
20131,462
2014849
2015691
20162,670
2017799
2018842
2019668
2020579
2021453
2022375
2023241
2024467
2025199
2026119

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,169 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
sunburnSignal37392.383.331,932
photosensitivity reactionSignal41545.241.117,458
disease progressionSignal76811.510.77,311
rashSignal1,5546.36.07,003
alopeciaSignal5635.04.61,831
arthralgiaSignal1,0434.44.22,794
decreased appetiteSignal5344.03.71,229
pyrexiaSignal7443.83.51,539
fatigueSignal1,0392.32.2828
diarrhoeaSignal8282.32.1592
deathSignal1,0652.22.0698
nausea8121.81.7299
pruritus3901.81.6135
vomiting4751.81.6163
off label use8751.81.6295

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.